The global Hemostasis And Tissue Sealing Agents Market size is expected to reach USD 10.34 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.7% during the forecast period. The agents have gained popularity over time due to their ability to prevent blood loss. Rapid growth of minimal invasive technology and demand for faster recovery by patients is expected to promote market growth over the forecast period.
According to the Centers for Disease Control and Prevention
(CDC), approximately 150 million of American population is currently suffering
from at least one chronic condition, which leads to surgeries and even
mortality at times. An estimate over the rising incidence was made by the CDC,
which concluded that over 48% of the entire American population is expected to
suffer by chronic condition.
The hemostasis and tissue sealing agents market is
expected to witness lucrative growth over the next seven years owing to, an
increase in demand supported by rising surgery volumes. Growth in geriatric
population and prevalence of chronic conditions are the impact rendering
drivers for this industry.
Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/hemostasis-tissue-sealing-agents-market
Further key findings from the
report suggest:
- The
hemostats market is expected to expand at a CAGR of over 8.7% over the
forecast period owing to the rise in global volume of surgeries and
applicability of the product across a variety of surgeries to avoid
occurrence of hypovolemic shock, thrombocytopenia, blood transfusions, and
post-operative complications
- Flowable
hemostats are a combination of active and mechanical agents. They function
by blocking blood flow and also converting fibrinogen into fibrin for
coagulation. This segment is expected to witness a lucrative CAGR of over
10.0% from 2018 to 2026
- Some
key players operating in the hemostasis and tissue sealing agents market
include Johnson & Johnson; CryoLife Inc.; Pfizer; C R Bard; B Braun; Covidien;
and Smith & Nephew. Market participants are involved in technological
advancements to ensure sustainability and regional presence
- For
instance, in March 2015, Ethicon announced higher efficiency of EVARREST
fibrin sealant patch as compared to its substitute, TachoSil patch
(Baxter). Further study would be conducted at the St. Vincent Heart Centre
of Indiana to understand added advantages that the product can offer.
About Us:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment